Vertex Pharmaceuticals VRTX Europe — Product revenues, net
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's europe — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's europe — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported europe — product revenues, net of $950M in Q1 2026.
- How has Vertex Pharmaceuticals's europe — product revenues, net changed year-over-year?
- Vertex Pharmaceuticals's europe — product revenues, net increased by 14.9% year-over-year, from $826.6M to $950M.
- What is the long-term trend for Vertex Pharmaceuticals's europe — product revenues, net?
- Over 2 years (2022 to 2024), Vertex Pharmaceuticals's europe — product revenues, net has grown at a 13.0% compound annual growth rate (CAGR), from $2.71B to $3.45B.
- What does europe — product revenues, net mean?
- The total net revenue earned from selling pharmaceutical products in the European market.
- How do you interpret europe — product revenues, net?
- An increase suggests successful market penetration, strong demand for the company's therapies, or favorable pricing adjustments in the region. A decrease may indicate increased competition, regulatory pricing pressure, or a decline in patient adoption rates.
- How does europe — product revenues, net compare across companies?
- Comparable to regional revenue reporting for other global biopharmaceutical companies, often benchmarked against total international revenue growth rates.